Best Healthcare Penny Stocks Rallying Markets in 2026
Small-cap healthcare stocks are gaining traction in 2026 as trial milestones and funding flow refresh investor intere...
Biotech
Biotech insights await. This page curates 5 articles on Tempus, Moderna, Praxis, ImmunityBio and market moves to help you evaluate stocks and sharpen your portfolio strategy.
58 articles
Corcept Therapeutics Zoomed Nearly: What Fueled the Week
This week brought a notable rise for Corcept Therapeutics as investors reacted to a major catalyst. Learn what drove ...
Rockwell Medical (RMTI) Earnings: Key Takeaways for 2026
Rockwell Medical is a niche player in renal care. This analysis breaks down rockwell medical (rmti) earnings, what th...
America Handing MRNA Lead: Investors Reassess Biotech
A political shift in the United States is denting confidence in mRNA medicine, with funding drying up and manufacturi...
Precigen (PGEN) 2025 Earnings Outlook: What to Watch
As biotech earnings season unfolds, Precigen (PGEN) 2025 earnings take center stage. This guide breaks down what to m...
Investors Strapped Rocket Corcept: Why the Stock Jumped on Wednesday
A pivotal FDA decision sent Corcept Therapeutics stock soaring. This guide explains the news, what it could mean for ...
Prediction: Stocks That Will Outperform Summit in One Year
Spotlighting two strong growth names that could exceed Summit Therapeutics in a year. Learn the catalysts, risks, and...
This 6.5%-Yielding Dividend Payer Finds Fresh Ground
A high-yielding dividend payer is drawing attention as volatility grips markets. The company blends dependable income...
Insmed Reveals Japan Patient Surpasses U.S. Market
Insmed disclosed that Japan now hosts more MAC lung disease patients than the United States, a development that could...
MaxCyte (MXCT) 2025 Earnings Outlook for Investors
MaxCyte's 2025 earnings journey hinges on platform momentum, partnerships, and cash discipline. This guide breaks dow...
Dafna Capital Trims IShares ETF: Biotech Portfolio Moves
A major move by a prominent asset manager reveals how large portfolios tweak biotech bets. Learn what the trim means ...
Sellas Stock 346% Year Near Final REGAL Deaths Ahead
Sellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...